universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus in- fection. Eur J Gastroenterol Hepatol 2007;19:817-20. [CrossRef]
Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hep- atol 2011;8:275-84.
Chang LW, Liranzo M, Bergfeld WF. Cutaneous side effects asso- ciated with interferon alpha therapy:a review. Cutis 1995;56:144.
Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Dif- fuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C:a series of 20 patients. Br J Dermatol 2002;147:1142-6. [CrossRef]
Kartal ED, Colak H, Ozgunes I, Usluer G. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005;51:167-9. [CrossRef]
Vázquez-López F, Manjón-Haces JA, Pérez-Alvarez R, Pérez-Oli- va N. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C:the value of an interdisciplinary assessment. Br J Dermatol 2004;150:1046-7. [CrossRef]
Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus in- fection. Eur J Gastroenterol Hepatol 2007;19:817-20. [CrossRef]
Koga T, Shimizu A, Nakayama J. Interferon-gamma production in peripheral lymphocytes of patients with tinea pedis:comparison of patients with and without tinea unguium. Med Mycol 2001;39:87-90. [CrossRef]
Koga T. Fungal immunology in the skin;immune response to derma- tophytes. Nippon Ishinkin Gakkai Zasshi 2009;50:151-4. [CrossRef]
Grover C, Khurana A. Onychomycosis:Newer insights in patho- genesis and diagnosis. Indian J Dermatol Venereol Leprol 2012;78:263-70. [CrossRef]
Rosenthal SA, Stritzler R, Vilafane J. Onychomycosis caused by Aspergillus fumigatus. Report of a case. Arch Dermatol 1968;97:685-7. [CrossRef]
Ramos A, Ussetti P, Laporta R, Lazaro MT, Sanchez- Romero I. Cutaneous aspergillosis in a lung transplant recipient. Transplant Infect Dis 2009;11:471-3. [CrossRef] Balkan Med J 2013; 30: 131-2
Isolated Left Ventricular Diverticulum
Figure 3. Six months after discontinuation of therapy
Onychomycosis Case Developing during Interferon Treatment
Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hep- atol 2011;8:275-84.
Chang LW, Liranzo M, Bergfeld WF. Cutaneous side effects asso- ciated with interferon alpha therapy:a review. Cutis 1995;56:144.
Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Dif- fuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C:a series of 20 patients. Br J Dermatol 2002;147:1142-6. [CrossRef]
Kartal ED, Colak H, Ozgunes I, Usluer G. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005;51:167-9. [CrossRef]
Vázquez-López F, Manjón-Haces JA, Pérez-Alvarez R, Pérez-Oli- va N. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C:the value of an interdisciplinary assessment. Br J Dermatol 2004;150:1046-7. [CrossRef]
Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus in- fection. Eur J Gastroenterol Hepatol 2007;19:817-20. [CrossRef]
Koga T, Shimizu A, Nakayama J. Interferon-gamma production in peripheral lymphocytes of patients with tinea pedis:comparison of patients with and without tinea unguium. Med Mycol 2001;39:87-90. [CrossRef]
Koga T. Fungal immunology in the skin;immune response to derma- tophytes. Nippon Ishinkin Gakkai Zasshi 2009;50:151-4. [CrossRef]
Grover C, Khurana A. Onychomycosis:Newer insights in patho- genesis and diagnosis. Indian J Dermatol Venereol Leprol 2012;78:263-70. [CrossRef]
Rosenthal SA, Stritzler R, Vilafane J. Onychomycosis caused by Aspergillus fumigatus. Report of a case. Arch Dermatol 1968;97:685-7. [CrossRef]
Ramos A, Ussetti P, Laporta R, Lazaro MT, Sanchez- Romero I. Cutaneous aspergillosis in a lung transplant recipient. Transplant Infect Dis 2009;11:471-3. [CrossRef] Balkan Med J 2013; 30: 131-2
Isolated Left Ventricular Diverticulum
Figure 3. Six months after discontinuation of therapy
Tuna, N., Erdem, M. T., & Karabay, O. (2013). Onychomycosis Case Developing during Interferon Treatment. Balkan Medical Journal, 2013(1). https://doi.org/10.5152/balkanmedj.2012.115
AMA
Tuna N, Erdem MT, Karabay O. Onychomycosis Case Developing during Interferon Treatment. Balkan Medical Journal. January 2013;2013(1). doi:10.5152/balkanmedj.2012.115
Chicago
Tuna, Nazan, Mustafa Teoman Erdem, and Oğuz Karabay. “Onychomycosis Case Developing During Interferon Treatment”. Balkan Medical Journal 2013, no. 1 (January 2013). https://doi.org/10.5152/balkanmedj.2012.115.
EndNote
Tuna N, Erdem MT, Karabay O (January 1, 2013) Onychomycosis Case Developing during Interferon Treatment. Balkan Medical Journal 2013 1
IEEE
N. Tuna, M. T. Erdem, and O. Karabay, “Onychomycosis Case Developing during Interferon Treatment”, Balkan Medical Journal, vol. 2013, no. 1, 2013, doi: 10.5152/balkanmedj.2012.115.
ISNAD
Tuna, Nazan et al. “Onychomycosis Case Developing During Interferon Treatment”. Balkan Medical Journal 2013/1 (January 2013). https://doi.org/10.5152/balkanmedj.2012.115.
JAMA
Tuna N, Erdem MT, Karabay O. Onychomycosis Case Developing during Interferon Treatment. Balkan Medical Journal. 2013;2013. doi:10.5152/balkanmedj.2012.115.
MLA
Tuna, Nazan et al. “Onychomycosis Case Developing During Interferon Treatment”. Balkan Medical Journal, vol. 2013, no. 1, 2013, doi:10.5152/balkanmedj.2012.115.
Vancouver
Tuna N, Erdem MT, Karabay O. Onychomycosis Case Developing during Interferon Treatment. Balkan Medical Journal. 2013;2013(1).